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ABSTRACT: Illicit heroin use is a worldwide problem, with significant health and social costs. 
Treatment is known to be effective in changing heroin use habits, but it often needs to be 
provided over a lifetime, with people cycling in and out of treatment. It is therefore important to 
INTERNATIONAL JOURNAL OF MICROSIMULATION (2016) 9(3) 140-176  141 
RITTER, SHUKLA, SHANAHAN, VAN HOANG, LAM CAO, PEREZ, FARRELL Building a Microsimulation Model of Heroin Use Careers in Australia  
capture a long-term perspective on heroin use careers. The aim of this project was to build a 
lifetime microsimulation model of heroin using careers. This paper describes the conceptual 
logic of the model, the input parameters and the verification and validation results. A 
microsimulation model was chosen as the most appropriate simulation platform with 9 states, 
and 111,400 individuals (aged between 18 and 60) each with gender, HIV (human 
immunodeficiency virus) and HCV (hepatitis C) status, and treatment history. Probabilities 
associated with crime commission and individually calculated lengths of stay in each state were 
determined from multiple datasets. The model included costs associated with treatment 
provision, healthcare services, criminal activity, life years lost, and family benefit of treatment. 
The final model represented 42 years of a heroin use career for a cohort based on Australian 
(New South Wales) data. Individuals cycle into and out of heroin using states (including 
abstinence), as well as treatment and prison states. We were able to build a stable, tractable 
model and verified all parameters. Validation against external data sources revealed high validity. 
While there are limitations associated with any model, the heroin career model now has the 
potential to be used for simulations of alternate policy scenarios. 
 
KEYWORDS: Microsimulation model, heroin, opioids, lifetime model  
 
JEL classification: C15, C63, I12  
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1 INTRODUCTION 
Heroin is an illegal drug that is widely abused. It is estimated that there are around 16.5 million 
heroin users worldwide (a 0.4% population prevalence rate). This does not include 
pharmaceutical opioid misuse, which is growing at a very fast rate (United Nations Office on 
Drugs and Crime, 2015). Australia has one of the higher rates of heroin use internationally and is 
estimated to be around 1% of the general population (Australian Institute of Health and Welfare 
[AIHW], 2013a). In Australia, heroin is purchased on the black market and usually injected. A 
person dependent on heroin will inject three to four times a day, and will experience withdrawal 
symptoms if they reduce or cease using heroin. The costs to society of heroin use and 
dependence are substantial and include both healthcare costs and the costs associated with crime. 
The social costs of illicit drugs has been estimated to be AUD$8,189 billion (Collins & Lapsley, 
2008) in Australia with similar per capita estimates from other nations (European Monitoring 
Centre on Drugs and Drug Addition [EMCDDA], 2008, 2011, 2014). Given the size of the 
economic burden, it is not surprising that governments across the globe expend considerable 
funds in trying to better manage illicit drugs. In Australia, the federal and state governments 
spend about AUD$1.7 billion per annum in prevention, treatment, harm reduction and law 
enforcement to combat illicit drugs (Ritter, McLeod, & Shanahan, 2013). Of the total spending, 
the majority was allocated to law enforcement, leaving a small proportion to prevention, 
treatment and harm reduction. There is increasing pressure from both the government and the 
public to know whether the current spending is optimal or what needs to change to increase the 
benefits of spending. This is particularly important for complicated social problems, such as 
heroin use, where there are many external costs. 
 
In light of both the high social cost associated with illicit drugs and the extent of government 
expenditure, it is vital that resources are invested in the best possible way. While existing research 
has demonstrated the efficacy and relative cost-effectiveness of heroin treatments notably 
pharmacotherapy maintenance such as methadone and buprenorphine (Barnett, 1999; Connock 
et al., 2007) there has to date been no analysis of the net social benefit of providing heroin 
treatment interventions over the life course. There is a pressing need to evaluate the existing 
combinations of heroin treatment interventions over a heroin using career, and explore the best 
combinations that provide the highest net social benefits. 
 
The aim of this paper is to detail the development of a microsimulation model (MSM) for heroin 
use which can be used to assess the net social benefit of current heroin treatment strategies, such 
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that the final model can be used to compare different combinations of treatment alternatives 
through modelled scenarios. This will lead to better informed policy decisions about the mix and 
type of treatments. 
 
The critical methodological issue is the choice of modelling approach. The model needs to 
capture recurring events over time, such as the common pattern of cycling in and out of heroin 
treatment (Bell, Burrell, Indig, & Gilmour, 2006) as well as reflect the heterogeneity amongst 
people who use heroin and their alternative trajectories. The chosen model is MSM. MSM 
depicts events and outcomes at the level of the individual. The MSM enables ‘memory’ for each 
individual of such things as the length of heroin use, past treatments and incarcerations. 
 
Heroin use careers with recurring events, such as abstinence, crime, incarceration, and treatment 
over time, can be modelled using an approach broadly classified as state transition models 
(STM). As per Siebert et al. (2012), a typical STM consist of a set of mutually exclusive and 
collectively exhaustive health states where individuals can transition among health states based 
on predefined transition probabilities. STMs are flexible and transparent computer-based 
decision making models which include both Markov model cohort simulation and individual-
based microsimulation. Cohort-based Markov model is one of the predominantly used STM in 
the substance abuse field (Schackman, Leff, Polsky, Moore, & Fiellin, 2012). Cohort-based 
Markov models are relatively simple to develop when the number of health states is not large. 
These models are restricted by the Markovian assumption, where transition probabilities do not 
depend on individual history or memory (i.e. past health states or state duration) (Siebert et al., 
2012). In the case of heroin use, it is recognised that an individual’s history of incarceration, 
treatment, and length of time in treatment has an effect on the state transition for that individual 
(Hser, Evans, Huang, & Anglin, 2004; Zhang, Friedmann, & Gerstein, 2003). Therefore, MSMs, 
which are not restricted by the Markovian assumptions and number of health states, are more 
appropriate for modelling heroin use careers. MSM reduces the number of health states required 
as it simulates an individual’s history by using tracker variables. 
 
MSMs better represent the heterogeneity among individuals in complex modelling scenarios such 
as illicit drug use. MSMs can model individual characteristics, treatment and heroin use history as 
continuous variables, whereby future transitions depend on current and past individual history. 
MSM has been widely used to evaluate health policies and other social and economic policies in 
many countries. It serves as an effective tool for policy evaluation, decision making and 
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allocation of scarce financial resources. Many large MSM models have been built in Australia and 
overseas (Briggs & Sculpher, 1998; Harding, Keegan, & Kelly, 2010; Karnon, 2003; Ringel, 
Eibner, Girosi, Cordova, & McGlynn, 2010; Rutter, Zaslavsky, & Feuer, 2011; Zucchelli, Jones, 
& Rice, 2012). However, there are very few MSM models that have been built to specifically 
evaluate illicit drug treatment policies (Hoang et al., 2016). It is noted that it is important to build 
an MSM specifically for a country/state due to the differences in health care financing structure, 
costs and benefits, as well as the substantial difference in the availability of treatment methods 
and drug use.  
 
There are two existing MSM in our content domain, both from the USA. The RAND Marijuana 
micro simulation model simulates the use of marijuana over the life course in the USA (Paddock, 
Kilmer, Caulkins, Booth, & Pacula, 2012). The model follows a cohort of 12 year olds 
representative of the United States population in 2004, and its focus is on the epidemiology of 
marijuana use. The second model, by Zarkin et al. (2005) models the costs and benefits of 
methadone treatment related to heroin use, criminal activity, labour market participation and 
health care utilization. This model follows 1,000,000 individuals from 18 to 60 year olds who are 
representative of the United States population. Despite taking into account the life-course 
perspective of illicit drug use, these two existing models are limited by only containing a few 
states of drug use, and in the case of Zarkin et al. (2005) a focus on a single treatment 
(methadone maintenance) and a number of simplifications about internal and external costs and 
benefits. Our goal was to develop a detailed model of heroin careers for one Australian 
jurisdiction, i.e. New South Wales (NSW) which enabled assessment of the net social benefit of 
treatment and the opportunity to simulate alternate treatment scenarios such as different 
combinations of treatment modalities over the lifetime of heroin use. 
 
This paper proceeds as follows: we provide an overview of the model and its components, 
(section 2), then detail the parameterisation and data sources for each of the model components 
(section 3). Section 4 provides details of the cost elements within the model, followed by the 
verification and validation results (section 5). The paper concludes with a discussion of both the 
strengths and limitations of the approach taken here as well as considering the future 
applications of the model. 
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2 MODEL OVERVIEW 
The MSM model for heroin use careers takes the population of individuals who have ever used 
heroin (previously and currently) for one Australian state (NSW) including those who used 
heroin previously and are currently abstinent, those in treatment subgroups as well as those in 
prison. Each individual in the initial population is characterised by his/her age, gender, treatment 
history (number of episodes and duration of treatment), human immunodeficiency virus (HIV) 
and hepatitis C (HCV) status. Each individual evolves over his/her simulated lifetime and 
eventually transitions from one state to another one. 
 
There are nine mutually exclusive states, which represent the major modalities of a heroin use 
career: heroin use, in treatment, abstaining, in prison. Three drug-using states (in absence of 
treatment), are represented in the model: i) abstinence, ii) irregular use, and iii) 
regular/dependent use. For the community treatment states, four mutually exclusive states were 
included: i) withdrawal from heroin (detoxification), ii) residential rehabilitation (RR), iii) Opioid 
Substitution Treatment (OST), and iv) counselling only. There are two prison states: in prison 
without treatment; and in prison and in receipt of OST. Exit from the model occurs if an 
individual is still alive at age 60, or if death from drug related or non-drug related causes occurs 
prior to age 60. 
 
The population of individuals are transitioned from one state to another using predefined 
(individually based) state transition probabilities. In this model, an approach which provides 
heterogeneous ‘time to transition’ for each individual is used. The length of stay (LOS) in each 
treatment, heroin use and prison episode is drawn from LOS distributions. LOS was chosen 
because it is highly predictive of subsequent drug use and treatment outcomes (Hser et al., 2004; 
Zhang et al., 2003). 
 
Each state is associated with costs (and benefits) which depend on both fixed costs (such as the 
cost of one day in treatment) and variable costs, such as the LOS for any one individual. The 
costs and benefits that were valued in this model were: (i) heroin treatment costs; (ii) other health 
care utilisation; (iii) treatment for specific diseases such as HIV, HCV; and (iv) crime and 
criminal justice system costs (police, courts, prisons and social costs of crime). Benefits include: 
earnings due to individuals returning to work after successful treatments; and value of treatment 
to the family. 
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3 DATA SOURCES AND PARAMETERISATION OF THE MODEL 
3.1 Mutually exclusive states 
The determination of the finite number of states for a simulation is often difficult, as the real 
world demands many different states but the reality of data and computation requires simplicity. 
In this simulation of heroin careers, we chose 9 mutually exclusive states: 3 drug using states; 4 
community treatment states and 2 prison states. The definition for each state is given in Table 1. 
 
Table 1: Mutually exclusive states and their definition 
State Definition 
Abstinence (S1)  Individuals in this state are not using heroin but have used heroin at 
some previous time. 
Irregular use (S2) Individuals in this state use heroin irregularly, as defined as 1 to 3 
days a month, or a maximum of 1 or 2 days a week. They do not 
ever develop dependence. 
Regular/dependent 
heroin use (S3)  
Individuals in this state use heroin regularly (defined as more than 3 
days per week in the last month) and they are not in receipt of any 
type of treatment.  
Withdrawal (S4)  Individuals in this state receive withdrawal treatment for their 
heroin dependence. Withdrawal treatment is concerned with neuro-
adaptation reversal, involves about 5-7 days care (in an inpatient or 
outpatient setting) and includes medications to manage symptoms, 
supportive care and case management. In this model it is 
characterised as residential withdrawal (for the purposes of unit 
costing), and excludes long-tern tapered methadone withdrawal. 
Residential 
rehabilitation (RR) (S5)  
Individuals in this state receive residential rehabilitation for their 
heroin dependence. RR is concerned with behavioural change 
across all life areas, including relapse prevention, psychological well-
being, physical health, nutrition etc. It is provided in residential 
settings, and an ideal treatment program is 6-9 months long 
although many will leave in the first week. While some RR in 
Australia also provide OST as part of the program, as characterised 
here this RR does not include OST. 
Opioid Substitution Individuals in this state receive Opioid Substitution Treatment for 
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Treatment (OST) (S6) their heroin dependence. The provision of a legal, safe opioid (either 
methadone or buprenorphine), dispensed daily or less frequently 
with take-away doses; requires a prescriber and attendance at a 
pharmacy (primary care or clinic settings). The model does not 
distinguish between methadone and buprenorphine. 
Counselling Only (S7)  Individuals in this state receive counselling for their heroin 
dependence. Provision of psychological therapy only, on an 
outpatient basis (weekly or fortnightly) with case management.  
In-prison no treatment 
(S8) 




Individuals in this state are in prison, have a history of heroin use, 
and are in receipt of OST in prison.   
 
In summary, we have selected a set of mutually exclusive states large enough to capture the 
complexity of the treatment process and few enough to ensure the resulting model is tractable 
and does not overburden the model with very detailed and specific data requirements. 
3.2 Initial population 
The initial population is distributed across each of the 9 states in the model (S1-abstinence; S2-
irregular use; S3-regular/dependent use and no treatment; S4-withdrawal; S5-residential 
rehabilitation; S6-OST; S7-counselling; S8-prison; and S9-prison treatment). The figures for each 
state were derived from various data sources applicable to NSW and/or Australia where NSW-
specific data were not available. The number of individuals in the four community treatment 
states were calculated first (with data from administrative records representing either episodes of 
care over one year, or census data – single day (AIHW, 2013b, 2013c). The prison treatment 
numbers were also taken from administrative records (AIHW, 2013c). This resulted in 
approximately 19,000 individuals undertaking some form of treatment.  
 
This figure was then used to estimate the numbers of individuals in S3 (dependent use, no 
treatment). This was done by applying ‘unmet need for treatment’ estimates from Australian 
research (Chalmers, Ritter, Heffernan, & McDonnell, 2009) and other confidential data sources. 
A range of estimates was obtained (between a low of 4,434 people and a high of 36,356). In the 
absence of better data, we used the mean of the estimates (16,500).  
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For the prison populations, we know that of the total 9,897 prison population in NSW 
(Australian Bureau Statistics, 2013), 30.6% NSW inmates report heroin use prior to their prison 
term (Kevin, 2005). We also know that there were 1,661 in OST in prison at any point in time 
(AIHW, 2013c), indicating that there were similar number of those who have used heroin prior 
to imprisonment that are not on OST. We also adjusted for remand numbers: NSW Criminal 
Courts Statistics Reports (see 
http://www.bocsar.nsw.gov.au/Pages/bocsar_court_stats/bocsar_court_stats.aspx) noted that 
approximately 29% of prisoners were on remand. The final population numbers for the prison 
states were reduced by this amount.  
 
Finally, we required the numbers of abstinent (S1) and irregular (S2) heroin users. The average 
rate of abstinence amongst Australian heroin users was estimated in the longitudinal Australian 
Treatment Outcome Study (ATOS) (Darke et al., 2007; Ross, 2004 and own analyses) revealing a 
mean percentage abstinence at each of the follow-up points (3, 12, 24, and 36 months) to be 
25%, based on the mean % of abstinence from ATOS at 3, 12, 24 & 36 months (12.27, 21.71, 
32.53, 34.65 respectively. The 25% was applied to the existing population numbers for heroin 
use (which was S3 through to S9 inclusive) to establish the population number for S1. For the 
number of irregular, non-dependent and not-in-treatment people using heroin in NSW (S2), Day 
et al. (2006) reported a multiplier of “2.5 recreational heroin users to regular heroin users”. They 
derived the 2.5 multiplier from two sources (the NSMHWB ratio of past year heroin use to 
opioid dependence, and a BOCSAR report (Weatherburn & Lind, 1997). Using this method 
would give an estimate of 62,380 in S2. However, other data sources suggest a lower multiplier 
of 1.5 (AIHW, 2010; Stafford, 2013). We took the main estimate to be close to a 1.5 multiplier 
(rather than the higher 2.5), resulting in an S2 population of 53,000. 
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Table 2: Initial population by state 
State Starting number 
S1 abstinent 22,000 
S2 irregular ongoing use 53,000 
S3 regular, dependent use 16,500 
S4 withdrawal 20 
S5 Therapeutic community 80 
S6 OST 17,500 
S7 counselling 100 
S8 prison not in treatment  1,100 
S9 prison in treatment  1,100 
TOTAL starting population 111,400 
 
In describing the initial population at time zero in the model, we also defined the basic 
characteristics of each individual at the start. The following characteristics were used: age; 
gender; number of treatment episodes; HIV status and HCV status. We obtained the unit record 
ATOS data (Darke et al., 2007; Darke, Ross, et al., 2005; Ross et al., 2004; Shanahan et al., 2006) 
for the ATOS baseline, 3, 12, 24 and 36 month interviews and used the unit record data for a 
number of parameters (henceforth referred to as ATOS data). Participants had the same 
distributions of age, gender and number of treatment episodes in all states at baseline.  
 
To estimate the number of individuals at baseline in the model who were HCV positive, we used 
NSW-specific data (Shand et al., 2014) indicating that 85% of clients tested in OST treatment 
were anti-HCV positive and 65% of these were RNA (ribonucleic acid) positive. Applying the 
85% antibody HCV positive to our study population results in 95,471 individuals of whom 
62,056 were RNA positive. The number of baseline HIV positive cases was estimated from 
NSW surveillance data (The Kirby Institute, 2014) resulting in 300 existing cases. People who are 
HCV and HIV positive were assigned randomly based on age groups at the start of the model to 
meet the estimated numbers of HCV and HIV cases, and for HCV according to state of disease 
progression (National Centre in HIV Epidemiology and Clinical Research, 2009). The acquisition 
of HCV over the course of the model (newly acquired HCV cases) was estimated from the 
annual incidence rate (5.9 per 100 PY (4.4 to 7.5) (The Kirby Institute, 2013) of those who are in 
a drug using state in a given year and who do not already have HCV. Eighteen new HIV 
infections were included per annum.  
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3.3 Transition probabilities 
The model simulates life trajectories of these 111,400 people based on the transition matrix, 
which provides all possible transitions from one state to other states over participants’ lifetime. 
The possible transitions are determined by the availability of treatment modalities in NSW and 
characteristics of heroin use such as participating in treatment, abstinence, relapse, and so on. 
Multiple datasets and published literature were used or combined to estimate the parameters for 
transition functions/probabilities. 
 
We approached the development of individual transitions in a two-step fashion. In the first step 
we established a generic probability for transition from one community state to another. In the 
second step we then introduced individual characteristics which influence the generic (or base 
case) transition. Two data sources were used: the ATOS data (Darke, Mills, Ross, & Teesson, 
2011; Darke et al., 2007; Darke, Ross, et al., 2005; Darke, Williamson, 2005; Ross et al., 2006; 
Shanahan et al., 2006; Teesson, Havard, Ross, & Darke, 2006; Teesson et al., 2007); and 
published research from both Australia and overseas. The ATOS is a longitudinal dataset that 
follows heroin users in Australia since 2001-2002. There were 825 heroin users who were 
interviewed at the baseline in 2001-2002, of whom 277 entered maintenance therapy, 288 entered 
withdrawal treatment, 180 entered residential rehabilitation and 80 were recruited while not in 
any treatment. The participants were then re-interviewed at 3, 12, 24 and 36 months to observe 
the change in the modalities of treatment, as well as some critical aspects of heroin use such as 
demographics, criminal activities, health and employment over time. The transitions out of the 
modalities of treatment started at the baseline are expected to reflect the path/progression for 
people who use heroin. Using the ATOS unit record data, we identified 699 transitions in total. 
In some cases the cell sizes were small (less than 10); transitions to a current state were not able 
to distinguish S2 from S3 in the data; and previous states were limited to S4, S5, S6 and S7 (the 
prior drug using states were unknown). Nonetheless the data provided a starting point for 
establishing the probability of a transition from one state to another (see Table 3). 
 




State 1 State 2+3 State 4 State 5 State 6 State 7 Sum 
Previous 
state 
State 4 0.1822 0.4186 0.0000 0.1124 0.2209 0.0659 1 
State 5 0.4383 0.2222 0.0370 0.0000 0.1358 0.1667 1 
State 6 0.4015 0.4891 0.0219 0.0146 0.0000 0.0730 1 
State 7 0.4203 0.3188 0.0580 0.0435 0.1594 0.0000 1 
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These data needed to be triangulated with other research and literature, especially for the small 
cell sizes and those where no ATOS data existed. A systematic review of the heroin treatment 
outcome literature, which reported direct transitions from one state to another, was undertaken 
(Anthony, Warner, & Kessler, 1994; Day et al., 2006; Deacon, Hines, Curry, Tynan, & Day, 
2014; Gossop, Marsden, Stewart, & Kidd, 2003; Gossop, Marsden, Stewart, & Traecy, 2002; 
Hser, Hoffman, Grella, & Anglin, 2001; Hubbard, Craddock, & Anderson, 2003; Jimenez-
Treviño et al., 2011; Latkin, Knowlton, Hoover, & Mandell, 1999; Lenne et al., 2001; Mattick et 
al., 2001; Nosyk, Anglin, Brecht, Lima, & Hser, 2013; Price, Risk, & Spitznagel, 2001; Scherbaum 
& Specka, 2008; Waldorf, 1983; Zarkin et al., 2012; Zarkin et al., 2005). Additionally, current 
Australian administrative treatment data were used to estimate likely transitions. 
 
The estimates from the literature were then combined with the ATOS data, and using expert 
judgement we established a generic transition probability, as seen in Table 4. The most 
challenging aspect is combining the different types of data, weighting the Australian data more 
heavily and keeping in mind that most of the published literature (other studies, including ATOS 
and NEPOD (see Mattick et al. 2009)) are non-contiguous. That is, they report what the client 
status is at 3 or 12 months, but not what happened in-between (i.e. immediately after that 
treatment episode). Hence the ATOS data that we generated (specific to direct transitions 
between states) is likely to be the more reliable. The probabilities need to sum to 1.0, therefore 
they need to be adjusted across each row (which means one cannot take the single best estimate 
within any one cell but consider it in light of the other estimates across the whole row). This 
therefore entailed some further adjustments.  
 
Finally, one needs to recall that the vast majority of people who use heroin cycle rapidly; so most 
will actually land in S1 for at least one or two days after a treatment episode, but then quickly 
cycle out into S3 and then subsequently back into S4, 5, 6 or 7. So in this example, the 
probabilities in S1 appear higher than the reported abstinence rates in the literature but are then 
accommodated in the model through the LOS curves (which then adjust for how long someone 
stays in that state). 
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Table 4: Final base transition probabilities used in the model 
From:                   To: S1 S2 S3 S4 S5 S6 S7 
S1 Abstinence    1.0     
S2 Irregular use 1.0       
S3 Dependence 0.04   0.01 0.03 0.90 0.02 
S4 Withdrawal 0.18  0.52  0.05 0.20  0.05 
S5 Residential rehab 0.40  0.40   0.10 0.10 
S6 OTP 0.40  0.55 0.02 0.01  0.02 
S7 Counselling 0.30  0.50 0.05 0.05 0.10  
 
The second step in establishing transition probabilities entailed taking into consideration 
individual characteristics, which may influence the likelihood of an individual transitioning based 
on his/her age, gender, treatment history, and LOS. These three variables were selected because 
each of these three has been shown across many studies to be associated with trajectories or 
careers of heroin use.  
 
The criteria by which we determined whether to include a variation for these characteristics 
included: whether there was sufficiently robust evidence across contexts (e.g. from different 
countries, published research) that it is a known predictor; and whether there is also supporting 
Australian evidence, given that the model is Australian. In summary, we found three adjustments 
that met these criteria: the transition from S3 into S6 is adjusted by age (more likely if between 
20 and 29 years of age); the transition into any treatment state is adjusted by gender (females 
more likely to be in treatment); and longer LOS in S5 and S6 increases the probability of 
transition to S1 compared to S3. 
 
The transition probabilities from any community state into prison relied on crime data, court 
data and sentencing data. The rate of offending in the population was determined from the 
published results of a study about engagement with the criminal justice system among opioid 
dependent people in NSW using the linked dataset of the Pharmaceutical Drugs of Addiction 
System and the Bureau of Crime Statistics and Research Re-offending Database (Degenhardt et 
al., 2013; Gisev et al., 2014). The probability that a crime would result in imprisonment in the 
model was determined by gender (male or female), the state that the person was in (with lower 
rates when in treatment states), the age of the person (with lower imprisonment rates for older 
individuals) and the treatment history (with higher rates for those not ever been in treatment).  
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Having established the probability that any one individual would enter prison, the assignment to 
S8 (no treatment) or S9 (OST in prison) followed logic: those individuals from S6 continued 
their OST treatments and all individuals from S7 started OST treatment in prison, therefore, they 
go to the S9 state. Individuals from S4 and S5 were assumed to move to no treatment in prison 
(S8). Individuals from S3 were allocated to one of the two prison states based on data about 
heroin use and treatment before and after prison from an inmate population (Drug Use in Prison 
[DUIP]) survey (Kevin, 2013). Individuals from S1 were allocated to S8.  
 
The final set of transitions concerned moving out of prison and into the community. Individuals 
in prison without OST (S8) were assumed to move to the abstinence state (S1). The in-prison 
treatment individuals (S9) were assumed to move to abstinence (S1), irregular use (S2) or 
continue OST treatment in community (S6) with probabilities based on prior research (Larney, 
Toson, Burns et al., 2011). 
3.4 Time step and length of stay 
The time-step for each transition is delimited by the state (because average lengths of stay in 
some of the states are short (7 days) and for some states long (i.e. 6 months or 1 year). Individual 
lengths of stay reflect the heterogeneity of individuals moving between different states. Each 
‘time to transition’ is determined for each individual probabilistically based on a distribution of 
LOS within each state coupled with individual characteristics. The model calculates the time to 
next event using individual characteristics (e.g. state, age, others). As such, time to transition (in 
days) is continuous in nature. Multiple data sources were used to establish an LOS distribution 
for each state. These data combined the ATOS data, literature and administrative data available 
in NSW, as detailed in Table 5.  
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Table 5: Summary of data sources for LOS estimation 
State LOS data sources 
S1: Abstinence ATOS Dataset, (Hser, 2007; Nosyk et al., 2013; Shah, Galai, 
Celentano, Vlahov, & Strathdee., 2006; Simpson & Marsh, 1986; 
Termorshuizen, Krol, Prins, & Van Ameijden, 2005) 
S2: Irregular use ATOS Dataset, (Coffin & Sullivan, 2013; Grönbladh & Gunne, 
1989) 
S3: Regular use  ATOS Dataset, (Bell et al., 2006)  
S4: Withdrawal ATOS Dataset 
Alcohol and Other Drug Treatment Services National Minimum 
Data Set (AODTS-NMDS) Dataset  
S5: Residential Rehab ATOS Dataset 
AODTS-NMDS Dataset 
S6: OTP ATOS Dataset, (Burns et al., 2009) 
S7: Counselling  ATOS Dataset 
AODTS-NMDS Dataset 
S8, S9: Prison states All LOS determined by crime type (probability) and then the 
average sentence for that crime type (BOCSAR Court Data Report, 
2012, see NSW Bureau of Crime Statistics and Research. 
http://www.bocsar.nsw.gov.au ).  
 
A combined distribution for each state was created by using different data sources on LOS. To 
improve model sensitivity we created the final distribution (in days) from the monthly combined 
distributions using the specialist distribution software-EasyFit (MathWave, 2014). The 
procedures are as follows: first, a range of distributions were fitted to the raw data distribution; 
second, the goodness of fit test was conducted to determine the best fit, that is to find a 
distribution that has “closest distance” to the data (for detailed description of the goodness of fit 
test see http://www.mathwave.com/articles/goodness_of_fit.html#ks); once the best goodness 
of fit was determined, 1000 random observations from the best fitted final distribution were 
generated to form a distribution of LOS for each state.  
 
The LOS could also potentially vary depending on individual characteristics (such as previous 
treatment episodes, age, gender, amount of drug use). Therefore, adjusted LOS based on 
individual characteristics were used only where sustained evidence exists (i.e. at least two 
empirical studies to confirm). The following adjustments to LOS were made based on individual 
characteristics: females had a longer LOS in S1 than males (Darke et al., 2007; Shah et al., 2006; 
Xia et al., 2015); the current episode of S1 was longer than the previous episode of S1 by 20% 
(Nosyk et al., 2013); if the number of previous treatment episodes >5, then LOS in a S3 episode 
decreases by 20% (Darke, Ross, et al., 2005; Shah et al., 2006); and three adjustments were made 
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to the LOS in S6 (based on Bell et al., 2006; Burns et al., 2009; Darke et al., 2007; Davstad, 
Stenbacka, Leifman, & Romelsjo, 2009; Hser, Grella, Chou, & Angelin, 1998; Parmenter et al., 
2013; Peles, Kreek, Kellogg, & Adelson, 2006): older people stayed longer in S6 than younger 
people; females stayed longer; and subsequent episodes were longer than previous episodes.  
3.5 Mortality 
The mortality rate amongst people who use heroin is significantly elevated relative to the general 
population (Degenhardt, Larney, Randall, Burns, & Hall, 2014; Hall, Degenhardt, & Lynskey, 
1999; Larney et al., 2014). In addition, the mortality rate varies depending on heroin use status – 
for active heroin users the mortality rate is much higher than for those in stable treatment. A 
further complexity is that the mortality rate also varies depending on stage of treatment (or how 
long someone has been in treatment). For example, for OST (our S6), there is a heightened risk 
of mortality in the first week of treatment, after which time the mortality risk is much lower. For 
these various reasons, each state required its own mortality rate, and then within state, the LOS 
also determined mortality within state. The published Australian literature on mortality rates for 
people who use heroin was reviewed, and the mortality rates used in the model are detailed in 
Table 6.  
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Table 6: Crude mortality rates for individuals based on the state and length of stay 
State: To State: From  LoS  CMR (Crude Mortality 
Rate) (all cause) 
Source 
S1 Any Fixed rate across 
LoS 
5.3 /1000 PY (5.0-5.6) (Degenhardt et 
al., 2009) 
S2 Any Fixed rate across 
LOS 




S3 S1, S4, S5, S7  1st week  
2nd week 
17.4/1000 PY (11.7-25.0) 
20.1/1000 PY (13.8-28.4) 
(Degenhardt et 
al., 2009) 
S8  1st 2 weeks out of 
prison 
59.5/1000 PY (41.3-83.6) (Degenhardt et 
al., 2014) 
S2, S6, S9  For the rest of 
LoS  
11.5/1000 PY (11.1-12.0) (Degenhardt et 
al., 2009) 
S4 Anywhere Fixed 6.0/1000 PY (5.7–6.4) 
S5 Anywhere Fixed 6.0/1000 PY (5.7–6.4) 
S6 S3, S4, S5, S7, 
S8 
1st week of LoS 
2nd week 
39.5/1000 PY (31.9-48.8) 
17.0/1000 PY (11.8-23.6) 
S9 1st week of LoS 10.9/1000 PY (4.0-23.8) (Degenhardt et 
al., 2014) 
S6 All other times  5.6/1000 PY (5.2-5.9) (Degenhardt et 
al., 2009) S7 S3, S4, S5, S6 Fixed 6.0/1000 PY (5.7-6.4) 
S8 Any Fixed 2.7/1000 PY ( 1.2 - 2.2) (Larney et al., 
2014) S9 Any Fixed 0.7/1000 PY (0.3 to 1.2) 
 
4 ESTIMATING COSTS  
The costs and benefits included in this study were:  
 Costs  
o Heroin treatment  
o Other healthcare utilization   
o HIV/AIDs (aquired immunodeficiency syndrome) & HCV treatment  
 Criminal justice system (police, courts, prison, social cost of crime) benefits  
o Productivity 
o Life years saved (value of life year)  
o Value to family of treatment 
 
Heroin treatment costs: The primary source for resource use information for treatment was 
extracted from individual care plans developed for the National Drug and Alcohol-Clinical Care 
and Prevention (DA-CCP) (DA-CCP - the Drug and Alcohol - Clinical Care and Prevention 
(DA-CCP) planning tool commissioned by the Ministerial Council on Drug Strategy and 
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undertaken by the NSW Ministry of Health as an InterGovernmental Committee on Drugs 
(IGCD) project, 2013). Care plans for opioid substitution, withdrawal, residential rehabilitation, 
and counselling for populations aged 18 to 64 were used. Information on staff type and time, 
pharmaceuticals, diagnostics, overhead and administrative allocations were obtained from 
respective care packages for each treatment. Once identified, resources were valued at 2012 
AUD, sourced from NSW Wages and Salaries, Medical Benefit Schedule, Pharmaceutical 
Benefits Schedule (New South Wales [NSW] Health 2015, PBS 2015 (see 
http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home), MBS 2015 
(see http://www.pbs.gov.au/pbs/home;jsessionid=1mcv0rc5kdl7y1qxttkmtx8rue). Additional 
information on doses and dosing was obtained from relevant sources (Doran et al., 2006; 
Larance et al., 2014). Costs were estimated for an episode, and then a cost per day was calculated 
for use in the model. Costs for OST received in prison were modelled on the approach outlined 
by Warren et al. (2006), with costs estimated for both methadone and buprenorphine.  
 
Other healthcare utilization costs: Other health care utilisation costs were estimated in a two-step 
process. First, self-report data from the ATOS cohort on last month utilisation of inpatient, 
emergency department, outpatient services, general practitioners, specialists, and ambulances by 
model state were obtained. Then, relevant unit costs were applied (Department of Health [DoH], 
2014; (National Hospital Cost [NHC], 2015; NSW Health, 2015). These costs were then 
converted to daily costs and applied in the model.  
 
HIV/AIDs and HCV treatment costs: The treatment costs for HCV treatment were estimated for 
each stage of the disease, the likely success rate of the treatment, and the current government 
cost per person (The Kirby Institute, 2014; Visconti, Doyle, Weir, Shiell, & Hellard, 2013). The 
HIV treatment costs used a weighted average cost for treatment based on the current 
distribution of CD counts and relevant clinical costs (National Centre in HIV Epidemiology and 
Clinical Research, 2009; Schneider, Gray, & Wilson, 2014; The Kirby Institute, 2014).  
 
Criminal justice system costs: The costs of policing were estimated using the approach adopted by 
Byrnes et al. (2012), with annual non-capital expenditure on policing (Productivity Commission, 
2015; (RGS, 2013a). The average cost of a day in prison in NSW excluding capital costs was 
sourced from the Report on Government Services (Productivity Commission, 2015; RGS, 
2013c) as was the average cost per charge in the Magistrates Court (Productivity Commission, 
2015; RGS, 2013b), where the majority of all cases are heard. Social costs of crime were obtained 
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from an Australian report which included the intangible losses, property losses, and medical 
costs by type of offence (Smith, Jorna, Sweeney, & Fuller, 2013).  
 
Productivity: Participants who are in community states (and specifically S1, S2, S3, S6 and S7) can 
be employed. Probabilities of employment were derived from the ATOS dataset and the 
Melbourne Injecting Cohort study (Horyniak et al., 2013) and NSW Labour Statistics 2012. It 
was assumed that longer duration of abstinence and being in OST increased the probability of 
employment. If the simulated individual was employed, the benefit was calculated as equal to 
days of employment multiplied by earnings per day (for unemployed, the benefit was equal to 
zero). The mean weekly earnings by gender and age from the Employee Earnings Statistics 2012 
published by the Australian Bureau of Statistics was used to calculate the total earnings in a state. 
Therefore, benefits of employment was equal to the LoS (in days) times earnings per day.  
 
Value of statistical life year: It was beyond the resources of this study to derive a specific value of a 
statistical life year, therefore we turned to the literature. Previously, the Australian government 
commissioned a review of the literature, the methods and issues around the value of a statistical 
life (Access Economics, 2008). This review located 17 relevant Australian studies. The mean 
value of a life from these 17 studies was $5.7 million (range $0.9 to $28.4 million AUD in 2006). 
After further analysis, the recommendations from this report suggest using $6.0 million AUD in 
2006 (range $3.7 to $8.1 million). After adjusting to AUD from 2012 with the CPI, the value of a 
life was estimated to be $7.0 million (range $5.87 - $8.34 million AUD). This value was 
annuitized over 80 years with a 3% discount rate. Then the total value over the remaining 
expected lifespan was calculated, driven by age at death for each individual in the model.  
 
Value to family of treatment: A separate Discrete Choice Experiment study was undertaken to 
establish an appropriate value of the benefit of heroin treatment for family members. This study 
revealed that a family member was willing to pay AU$33.35 per week for treatment. We 
estimated that each person would have two family members, thus AU$66.70 was applied as a 
benefit (value) of treatment for every week a person was in treatment (S4, S5, S6, S7).  
 
Tables 7 to 11 provide the majority of the unit costs used in the model per participant, per day or 
per disease state. 
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Table 7: Heroin treatment costs 
State State description Per day costs (AUD) 
S1 Abstinence $0.00 
S2 Irregular Use $0.00 
S3 Dependent Use No Treatment $0.00 
S4 Withdrawal $410.77 
S5 Residential Rehab $139.36 
S6 Opioid Treatment Program $27.09 
S7 Counselling $18.49 
S9 Prison treatment $224.81 
 
Table 8: Other healthcare costs  
State State name Per month costs (AUD) 
S1 Abstinence $649.00 
S2 Irregular Use $649.00 
S3 Dependent Use No Treatment $441.00 
S4 Withdrawal $648.00 
S5 Residential Rehab $392.00 
S6 Opioid Treatment Program $860.00 
S7 Counselling $566.00 
S8 Prison No Treatment  $0.00 
S9 Prison Treatment $0.00 
 
Table 9: HIV and HCV treatment costs in AUD (per person per year) 
HIV treatment costs $20,678 
HCV treatment costs $15,526 
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Table 10: Crime costs (AUD) per offence  
Crime type Police costs Social costs 
Homicide and related offences $ 13,484.80  $2,731,649.19 
Acts intended to cause injury  $3,038.83  $2,650.68 
Sexual assault and related offences  $ 4,178.39  $3,959.32 
Dangerous or negligent acts endangering persons  $2,469.05  $2,904.72 
Abduction and other offences against the person  $4,273.35  $2,904.72 
Robbery or extortion and related offences  $7,312.18  $5,179.91 
Unlawful entry or burglary or break and enter  $3,988.46  $1,060.68 
Theft and related offences  $3,228.76  $2,883.83 
Fraud or deception and related offences  $3,133.79  $506.05 
Illicit drug offences  $2,753.94  0 
Prohibited and regulated weapons offences  $3,228.76  0 
Property damage and environmental pollution  $2,564.01  $1,060.68 
Public order offences  $3,703.57  $97.16 
Traffic and vehicle regulatory offences  $1,139.56  $97.16 
Offences against justice procedures  $3,703.57  $97.16 
Miscellaneous offences  $2,012.00  0 
COURT COST (Fixed)  $7,712 
 
Table 11: Capturing the resources relating to those who are charged and found not guilty and those who are found guilty but do not go to prison  
 2012 AUD – weighted by 




$3,090  those found not guilty 




$7,712  those found not guilty 




$1,144  those found guilty and not sentenced to 
prison 
 
For every person who goes to prison, 2 people will be found not guilty and costs were valued at 
$10,802 and 9 will be found guilty but not go to prison, valued at $11,946.  
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5 VERIFICATION AND VALIDATION 
Verification is the process of determining whether a computer program-based simulation model 
perform as it is intended, whereas validation refers to the process of determining whether the 
conceptual model (instead of computer program-based simulation model) accurately represents 
the real world system under study (Sargent, Kuhl, Steiger, Armstrong, & Joines, 2005).  
 
The simulation model was written in Java using the Eclipse IDE. The computer program was 
written following a modular approach (object orient programming) for model components. 
Several verification tests were defined for each of the modules to verify the intermediate 
simulation outputs. The logic for transition of individuals within the conceptual model was 
matched with the output from the simulation model using Eclipse IDE debugger. To verify that 
the conceptual logic was correctly coded in the computer program, we randomly selected 100 
individuals in the simulation model and traced their behaviour and matched that against 
conceptual logic. The transition summary from the model for these 100 individuals was manually 
compared against the expected transition summary. The transitions for these individuals matched 
the conceptual logic implemented in the computer program. In this situation, we verified the 
simulation response by running a simplified version of the simulation program with a known 
analytical solution. A simplified version of the model was run according to the changed 
parameters, i.e., age was fixed to 20 years, treatment history of individuals were assumed to be 1 
episode each of S4 – S7, LOS for all individuals was assumed to be 360 days, initial population 
was considered to be 100,000, mortality rates for HIV, Hep-C was assumed to be zero, and 
initial population was distributed equally from state 1 to 10 (i.e. 10,000 each). The analytical 
solution obtained by using the above mentioned parameters in the transition functions was then 
used to compare with the simplified simulation model.  
 
Mortality rate verification: The individual deaths from each state in a year were recorded to verify 
whether the mortality rate from the simulation model output was similar to the rates used in the 
input. Table 12 illustrates that the mortality rates from the simulation model were similar to the 
input rates. There were some minor differences in the rates due to the randomness in assigning 
crime probabilities in the model.  
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Table 12: Comparison of computed mortality rates from simulation and input rates 
State Mortality rate from simulation Input mortality rate (CI interval 95%) 
S1 0.0057 0.005 – 0.0056 
S2 0.0060 0.005 – 0.0056 
S3 0.0106 0.0111 – 0.0120 
S4 0.0047 0.0057 – 0.0064 
S5 0.0061 0.0057 – 0.0064 
S6 0.0057 0.0052 – 0.0059 
S7 0.0056 0.0057 – 0.0064 
S8 0.0024 0.002 – 0.0037 
S9 0.00038 0.0003 – 0.0012 
 
Imprisonment rates verification: Rates of imprisonment from the simulation model were compared 
against the input rates based on the simplified version of the model. Table 13 illustrates that the 
imprisonment rates from simulation model were similar to the input rates. 
 
Table 13: Comparison of computed imprisonment rates from simulation and input rates 
 From Simulation From the Input data 
 To S8 To S9 To S8 To S9 
S1 0.0022 - 0.0026 - 
S2 0.0286 - 0.0282 - 
S3 0.0404 0.0456 0.0408 0.0408 
S4 0.0414 0.0429 0.0408 0.0408 
S5 0.0400 0.0430 0.0408 0.0408 
S6 - 0.0784 - 0.0816 
S7 0.0427 0.0395 0.0408 0.0408 
 
Community transition rates verification: Transitions to community states were recorded and verified 
for correctness in the model. Table 14 illustrates that the community transition rates from the 
simulation model were similar to the input rates.  
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Table 14: Comparison of computed imprisonment rates from simulation and input rates 
Simulation output Input rates 
  S1 S2 S3 S4 S5 S6 S7   S1 S2 S3 S4 S5 S6 S7 
S1 -   -   1  -   -   -   -   S1 - - 1 - - - - 
S2 1  -   -   -   -   -   -   S2 1 - - - - - - 
S3 0.16 -   - 0.02 0.03 0.76 0.03 S3 0.154 - - 0.015 0.048 0.750 0.033 
S4 0.18 -   0.52 - 0.05 0.20 0.05 S4 0.18 - 0.52 - 0.05 0.20 0.05 
S5 0.60 -   0.33 - - 0.03 0.04 S5 0.60 - 0.34 - - 0.04 0.04 
S6 0.39 -   0.56 0.02 0.01 - 0.02 S6 0.40 - 0.55 0.02 0.01 - 0.02 
S7 0.30 -   0.50 0.05 0.05 0.10 - S7 0.30 - 0.50 0.05 0.05 0.10 - 
S8 0.30 -   0.60 - - 0.10 - S8 0.30 - 0.60 - - 0.10 - 
S9 -   -   0.10 - - 0.90 - S9 - - 0.10 - - 0.90  
 
Apart from these verifications, we also conducted verifications on the population aging, costs, 
benefits, state LOS, HIV and HCV infections and the associated illness progressions.  
 
Validation processes 
Two main data sources were used for model validation: the MIX dataset (Horyniak et al., 2013), 
which is a Victorian cohort of people who inject drugs (N=688 at baseline with four follow-ups), 
with an average age of 26 years at the start of the study. This dataset was not used to 
parameterise the model. ATOS conducted an 11 year follow-up of the original participants. 
While the ATOS data from baseline 3, 12, 24 and 36 months were used to parameterise parts of 
the model, the later (11 year) follow-up data were not used (Teesson et al., 2015). We also 
validated the model outputs against published research on mortality rates (e.g. Roxburgh & 
Burns, 2015). We ensured that the validation datasets were as closely matched as possible to the 
modelled data, so for example when we used the MIX dataset, given the young age of that 
cohort, we only took modelled results for simulated individuals between the ages of 18 and 30 
years.  
 
There are many sources of uncertainty in the model outputs: (i) stochastic events of moving to 
one of several states, and; (ii) model inputs such as LOS and transition probabilities. Therefore, 
each model run may produce a different set of outcomes, which may or may not closely match 
with the validated data sources. Monte Carlo simulation (running the model 100 times given the 
tight confidence intervals) was implemented to generate the mean/range/distribution of the 
outputs in order to verify with other datasets. 
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Six outputs from the model were validated against independent data sources: treatment patterns; 
heroin use; LOS/treatment exposure; criminal activity; imprisonment rate; and mortality rate. In 
relation to treatment patterns, there was excellent validation for the no treatment state 
movements (62% of the MIX sample, who were not in treatment at baseline, were not in 
treatment one year later. For our model this percentage was 63%). However, the simulated state 
transitions from OST did not match validation data: MIX showed that a large majority of 
participants remained in OST one year later (81%), whereas the model kept only 33% of 
individuals in OST one year later. The likely cause was the shorter LOS in S6, and the model 
insistence on individuals going to S1 (for at least one day) after S6. We undertook two 
adjustments to improve the model’s validity: revision to the S6 LOS and verification of the 
age/sex S6 formulae (which were initially incorrect). In the final model, the pattern from the 
MIX (validation data) was largely upheld, especially in the later years in the model. For S6, the 
MIX validation data show significantly increasing percentages over 5 years (from 36% at baseline 
to 67% at year 5). In the modelled result, the increase over the first five years is more modest 
(from 36% to 53%). However, by year 21, it is 68% and commensurate with the MIX data.  
 
The model’s outcomes are very closely matched with validated data regarding heroin abstinence 
from the 11 year ATOS study (75% in both modelled and validation data). This instils significant 
confidence in the model validity for an important outcome, i.e. heroin use. There also appears to 
be very good validation of the treatment exposure over time compared to ATOS year 11 results 
(median number of treatment episodes and days in treatment). As the treatment exposure in our 
model is driven by multiple transition probabilities, this is very reassuring.  
 
For the imprisonment and crime rates, we used ATOS 11 year self-reported data as the 
validation. The ATOS imprisonment rate was 10% by year 3; the model resulted in a prison rate 
of 6.02% by year 3. Arguably, therefore the imprisonment rate is low, relatively to the ATOS 
sample. On the other hand, the prison rate matches closely (verified) to the actual prison 
numbers in NSW (the data used to parameterise the model). The rates of detected crime, at 
around 20% accorded well with the ATOS rates (between 15% and 24%). The modelled rate at 
year 11 (16.7%) is lower than the ATOS rate at year 11 (22%), but is somewhat accounted for by 
exits from the model. 
 
In relation to mortality, across two different validation tasks, we find that the modelled mortality 
rate is possibly too low (using 11 year ATOS as validation) and too high (using actual NSW 
INTERNATIONAL JOURNAL OF MICROSIMULATION (2016) 9(3) 140-176  165 
RITTER, SHUKLA, SHANAHAN, VAN HOANG, LAM CAO, PEREZ, FARRELL Building a Microsimulation Model of Heroin Use Careers in Australia  
deaths from opioid-related causes in NSW). The differences are likely due to cohort effects, 
inasmuch as the NSW deaths research (Roxburgh & Burns, 2015) pertain to a time of high 
heroin purity and availability in NSW. Given the model was populated largely from data from 
this era (mortality rates as reported by Degenhardt et al (2009)), we would expect a better match 
with early 2000s mortality rates, rather than the later ATOS 11 year data, as has occurred.  
 
The final model, verified and validated, represents a 42-year history of a group of 111,400 
individuals who have used or are currently using heroin at the model commencement. Each 
individual commences in one state and then proceeds through multiple transitions over time, as 
they age, develop treatment experience, contract HCV and/or die before aged 60.  
 
6 DISCUSSION AND CONCLUSION 
The MSM model described in this paper simulates a range of treatment services in the 
community and prison, and uses a large variety of datasets from illicit drug use surveys and 
published literature. Traditionally, simulation models in the field of illicit drug use have been 
either short-term, or focussed on single treatment options and with a lack of consideration for 
individual histories and attributes.  
 
MSM are increasingly being used in health-care decision-making. These models have a better 
ability to represent the heterogeneity that is required in complex modelling scenarios such as 
illicit drug use. Individuals in these models accommodate their histories to influence the 
probabilities of the next transition without creating too large a number of health states. The 
model development described herein followed good modelling practice described in Karnon et 
al. (2012). The model has been verified internally by extensive logic reviews with domain experts 
and by analysing the simulation response by running a simplified version of the simulation 
program with known analytical solutions. All of these were consistent with expected modelling 
parameters and assumptions. Various features of the model were validated against external 
datasets and published data in this field, which were not used as an input for model 
parameterization. The model output seems coherent and does not significantly diverge from 
external datasets.  
 
The proposed model has, unsurprisingly, a number of limitations. In real-life, there are more 
than nine possible states for heroin use, including some other, relatively minor treatment types, 
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such as injectable heroin. It is not possible to represent every possible treatment state in the 
model: the data are simply not available and the model itself would become intractable. 
Additionally, there are gradations in heroin use. Our model somewhat crudely provides for three 
heroin use options: abstinence, irregular use or dependent use. While these three capture the 
broad array of heroin use, within each of the three, there can be much heterogeneity; for 
example our abstinence state (S1) includes both, those who are temporarily abstaining for a brief 
period of time, and those who have ‘recovered’ and will never resume heroin use. The 
parameterisation of LOS by individual characteristics overcomes this to some extent. In the 
prison states only one treatment type was considered (OST) for individuals receiving treatment 
in prison. This was due to the paucity of datasets informing different type of treatments received 
by drug using individuals. There was a lack of past research data to drive the mortality 
probabilities beyond those determined by state and LOS, but this is an important area for further 
work. Finally, the individual level model required a significant amount of data for modelling 
various aspects such as individual history, LOS, incarceration, mortality, and transitions to 
community. Moreover, the computational time required to run the model is generally higher than 
the simplified cohort based compartmental models. 
 
Having developed a verified and valid model of heroin use and its transitions for one Australian 
state (NSW), the deployment of the model for policy simulations can now commence. While 
there are many possible simulations, the most obvious initial ones to undertake are: increasing 
the availability/accessibility of treatment (for example through increasing the probability of 
inflow into treatment); and improving treatment outcomes (for example through increasing 
LOS). The main outcome of policy interest from these simulations is to compare the Net Social 
Benefit under the current status quo (that is the basecase model results) with the Net Social 
Benefit produced by the alternate scenarios. We hope that the policy simulations will provide 
economic data of relevance and value to current decision-makers. 
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